PUBLISHER: The Business Research Company | PRODUCT CODE: 1855991
PUBLISHER: The Business Research Company | PRODUCT CODE: 1855991
Targeted Alpha-Therapy Global Market Report 2025
Targeted alpha therapy (TAT) is a form of radiation therapy that delivers highly potent alpha-particle-emitting isotopes directly to cancer cells or diseased tissues. The therapy employs targeting molecules, such as antibodies, peptides, or small molecules, that specifically bind to cancer cell markers, allowing alpha particles to induce lethal double-strand DNA breaks in nearby cells while minimizing damage to surrounding healthy tissue.
The primary isotope types of targeted alpha therapy are actinium-225, radium-223, lead-212, bismuth-213, and others. Actinium-225 is a potent alpha-emitting radioisotope commonly used in targeted therapies due to its favorable half-life and decay properties. This therapy is applied in conditions such as prostate cancer, bone metastases, pancreatic cancer, and others. Key end users include hospitals, cancer research institutes, specialty clinics, and lymphoma treatment centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The targeted alpha-therapy market research report is one of a series of new reports from The Business Research Company that provides targeted alpha-therapy market statistics, including targeted alpha-therapy industry global market size, regional shares, competitors with a targeted alpha-therapy market share, detailed targeted alpha-therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted alpha-therapy industry. This targeted alpha-therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The targeted alpha-therapy market size has grown rapidly in recent years. It will grow from $0.87 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth during the historic period was driven by increasing regulatory approvals, growing emphasis on targeted therapy over conventional chemotherapy, expanded availability of alpha-emitting isotopes, rising government and private funding, and greater patient preference for minimally invasive therapies.
The targeted alpha-therapy market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth during the forecast period is fueled by rising prevalence of cancer and metastatic diseases, growing adoption of precision medicine, increasing awareness among oncologists and patients, higher research and development investments, and a growing number of clinical trials. The primary trends in the forecast period include advancements in radiopharmaceutical technology, technological developments in alpha-emitter production, integration of imaging and therapy, improvements in targeted drug delivery systems, and innovations in nuclear medicine technologies.
The increasing emphasis on precision medicine is expected to drive growth in the targeted alpha-therapy market. Precision medicine is an approach that tailors prevention, diagnosis, and treatment to an individual's genetic makeup, lifestyle, and environment, aiming for more effective outcomes. The rise of precision medicine is largely fueled by the growing availability of genetic testing, which allows for more accurate diagnoses and enables targeted treatments that lead to better patient outcomes. Targeted alpha-therapy plays a key role in precision medicine by delivering potent alpha-emitting isotopes directly to cancer cells. This method ensures precise treatment while minimizing damage to healthy tissues. For example, in March 2024, the American Pharmaceutical Review reported that global spending on precision medicine treatments reached nearly $32 billion in 2022, with projections to exceed $124 billion by 2027. As precision medicine continues to grow, it is expected to further drive the expansion of the targeted alpha-therapy market.
Companies in the targeted alpha-therapy market are innovating with solutions such as peptide receptor radionuclide therapy (PRRT) to improve cancer treatment efficacy, minimize off-target effects, and enhance patient outcomes. PRRT is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by binding them to peptides that specifically attach to receptors overexpressed on cancer cells. This helps to minimize damage to healthy tissues. For instance, in February 2024, RadioMedix Inc., a biotechnology company based in the US, partnered with Orano Med, a US-based pharmaceutical company, and received the first targeted alpha therapy to earn FDA breakthrough device designation. Their treatment, AlphaMedix (lead-212-Dotamtate), is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering high-energy alpha radiation directly to cancer cells, sparing healthy tissue. The advantage of this therapy lies in the short path length of alpha particles, which cause lethal DNA damage to tumor cells with minimal toxicity. This approach offers a promising new option for patients who have not responded well to or are naive to existing beta-emitter treatments, aiming to improve both efficacy and safety in treating difficult neuroendocrine tumors.
In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows AstraZeneca to advance its targeted alpha-therapy portfolio and transform cancer treatment by developing next-generation radioconjugate therapies. These new therapies aim to replace traditional chemotherapy and radiotherapy with more precise and targeted options. Fusion Pharmaceuticals Inc., a biotechnology company based in Canada, specializes in targeted alpha-therapy.
Major players in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.
North America was the largest region in the targeted alpha-therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in targeted alpha-therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the targeted alpha-therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The targeted alpha-therapy market consists of sales of neptunium-225 thorium-227 and astatine-211. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Targeted Alpha-Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on targeted alpha-therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for targeted alpha-therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The targeted alpha-therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Isotope Type: Actinium-225; Radium-223; Lead-212; Bismuth-213; Other Isotype Types
- 2) By Application: Prostate Cancer; Bone Metastases; Pancreatic Cancer; Other Applications
- 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Lymphoma; Other End Users
- Subsegments:
- 1) By Actinium-225: Ac-225 Lintuzumab; Ac-225 PSMA-617; Ac-225 DOTATATE
- 2) By Radium-223: Radium-223 Dichloride (Xofigo)
- 3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix); Pb-212 TCMC-Trastuzumab
- 4) By Bismuth-213: Bi-213 Lintuzumab; Bi-213 DOTATOC
- 5) By Other Isotope Types: Thorium-227; Astatine-211; Terbium-149
- Companies Mentioned: Bayer Aktiengesellschaft; Novartis AG; Lantheus Holdings Inc.; Telix Pharmaceuticals Limited; Eckert & Ziegler Strahlen- und Medizintechnik AG; Actinium Pharmaceuticals Inc.; RayzeBio Inc.; ITM Isotope Technologies Munich SE; ARTBIO Inc.; AdvanCell Pty Ltd.; IONETIX Corporation; Abdera Therapeutics Inc.; Aktis Oncology Inc.; Alpha-9 Oncology Inc.; Clarity Pharmaceuticals Pty Ltd.; Nucleus RadioPharma; Oncoinvent AS; PanTera; Perspective Therapeutics Inc.; RadioMedix Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Targeted Alpha-Therapy Market Characteristics
3. Targeted Alpha-Therapy Market Trends And Strategies
4. Targeted Alpha-Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Targeted Alpha-Therapy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Targeted Alpha-Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Targeted Alpha-Therapy Market Growth Rate Analysis
- 5.4. Global Targeted Alpha-Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Targeted Alpha-Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Targeted Alpha-Therapy Total Addressable Market (TAM)
6. Targeted Alpha-Therapy Market Segmentation
- 6.1. Global Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Actinium-225
- Radium-223
- Lead-212
- Bismuth-213
- Other Isotype Types
- 6.2. Global Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prostate Cancer
- Bone Metastases
- Pancreatic Cancer
- Lymphoma
- Other Applications
- 6.3. Global Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- Other End Users
- 6.4. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Actinium-225, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ac-225 Lintuzumab
- Ac-225 PSMA-617
- Ac-225 DOTATATE
- 6.5. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Radium-223, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Radium-223 Dichloride (Xofigo)
- 6.6. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Lead-212, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pb-212 DOTAMTATE (AlphaMedix)
- Pb-212 TCMC-Trastuzumab
- 6.7. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Bismuth-213, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bi-213 Lintuzumab
- Bi-213 DOTATOC
- 6.8. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Other Isotope Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Thorium-227
- Astatine-211
- Terbium-149
7. Targeted Alpha-Therapy Market Regional And Country Analysis
- 7.1. Global Targeted Alpha-Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Targeted Alpha-Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Targeted Alpha-Therapy Market
- 8.1. Asia-Pacific Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Targeted Alpha-Therapy Market
- 9.1. China Targeted Alpha-Therapy Market Overview
- 9.2. China Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Targeted Alpha-Therapy Market
- 10.1. India Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Targeted Alpha-Therapy Market
- 11.1. Japan Targeted Alpha-Therapy Market Overview
- 11.2. Japan Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Targeted Alpha-Therapy Market
- 12.1. Australia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Targeted Alpha-Therapy Market
- 13.1. Indonesia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Targeted Alpha-Therapy Market
- 14.1. South Korea Targeted Alpha-Therapy Market Overview
- 14.2. South Korea Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Targeted Alpha-Therapy Market
- 15.1. Western Europe Targeted Alpha-Therapy Market Overview
- 15.2. Western Europe Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Targeted Alpha-Therapy Market
- 16.1. UK Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Targeted Alpha-Therapy Market
- 17.1. Germany Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Targeted Alpha-Therapy Market
- 18.1. France Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Targeted Alpha-Therapy Market
- 19.1. Italy Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Targeted Alpha-Therapy Market
- 20.1. Spain Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Targeted Alpha-Therapy Market
- 21.1. Eastern Europe Targeted Alpha-Therapy Market Overview
- 21.2. Eastern Europe Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Targeted Alpha-Therapy Market
- 22.1. Russia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Targeted Alpha-Therapy Market
- 23.1. North America Targeted Alpha-Therapy Market Overview
- 23.2. North America Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Targeted Alpha-Therapy Market
- 24.1. USA Targeted Alpha-Therapy Market Overview
- 24.2. USA Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Targeted Alpha-Therapy Market
- 25.1. Canada Targeted Alpha-Therapy Market Overview
- 25.2. Canada Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Targeted Alpha-Therapy Market
- 26.1. South America Targeted Alpha-Therapy Market Overview
- 26.2. South America Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Targeted Alpha-Therapy Market
- 27.1. Brazil Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Targeted Alpha-Therapy Market
- 28.1. Middle East Targeted Alpha-Therapy Market Overview
- 28.2. Middle East Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Targeted Alpha-Therapy Market
- 29.1. Africa Targeted Alpha-Therapy Market Overview
- 29.2. Africa Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Targeted Alpha-Therapy Market Competitive Landscape And Company Profiles
- 30.1. Targeted Alpha-Therapy Market Competitive Landscape
- 30.2. Targeted Alpha-Therapy Market Company Profiles
- 30.2.1. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Telix Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
31. Targeted Alpha-Therapy Market Other Major And Innovative Companies
- 31.1. Actinium Pharmaceuticals Inc.
- 31.2. RayzeBio Inc.
- 31.3. ITM Isotope Technologies Munich SE
- 31.4. ARTBIO Inc.
- 31.5. AdvanCell Pty Ltd.
- 31.6. IONETIX Corporation
- 31.7. Abdera Therapeutics Inc.
- 31.8. Aktis Oncology Inc.
- 31.9. Alpha-9 Oncology Inc.
- 31.10. Clarity Pharmaceuticals Pty Ltd.
- 31.11. Nucleus RadioPharma
- 31.12. Oncoinvent AS
- 31.13. PanTera
- 31.14. Perspective Therapeutics Inc.
- 31.15. RadioMedix Inc.
32. Global Targeted Alpha-Therapy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Targeted Alpha-Therapy Market
34. Recent Developments In The Targeted Alpha-Therapy Market
35. Targeted Alpha-Therapy Market High Potential Countries, Segments and Strategies
- 35.1 Targeted Alpha-Therapy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Targeted Alpha-Therapy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Targeted Alpha-Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
